ALTERITY THERAPEUTICS LIMITED - Announcements

0.00%

1.5¢

Market Cap $138.1M

Healthcare Biotechnology

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company.... Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.More

Announcements

Filter Results

All Price Sensitive Only

ATH	Section 708A Notice		06/08/13	85.5KB	Share
ATH	Appendix 3B		05/08/13	186.63KB	Share
ATH	Prana prepares for next steps in the PBT2 development path		02/08/13	31.71KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/13	61.38KB	Share
ATH	Prana Doses 1st Patient in PBT2 Alzheimers Extension Study	PRICE SENSITIVE	29/07/13	30.03KB	Share
ATH	Prana Completes Phase 2 Huntington Disease Trial with PBT2	PRICE SENSITIVE	23/07/13	32.24KB	Share
ATH	Prana receives approval for open label extension study in AD	PRICE SENSITIVE	03/07/13	97.07KB	Share
ATH	Appendix 3B and Section 708A Notice		28/06/13	187.32KB	Share
ATH	Pranas PBT434 shows potential as treatment in PD	PRICE SENSITIVE	20/06/13	1.18MB	Share
ATH	New benchmark test to assess HD patients in clincial trials	PRICE SENSITIVE	19/06/13	527.83KB	Share
ATH	Prana Announces Share Purchase Plan Closed		03/05/13	30.29KB	Share
ATH	Appendix 3B		03/05/13	186.66KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/13	60.58KB	Share
ATH	Share Purchase Plan 2013 Offer Document	PRICE SENSITIVE	11/04/13	220.56KB	Share
ATH	Ceasing to be a substantial holder		11/04/13	32.34KB	Share
ATH	Appendix 3B		08/04/13	268.57KB	Share
ATH	Prana Announces Successful A$7 milion Capital Raising	PRICE SENSITIVE	27/03/13	28.21KB	Share
ATH	Trading Halt	PRICE SENSITIVE	27/03/13	159KB	Share
ATH	Prana details PBT2 data on reduced Tau Cognitive Impairment	PRICE SENSITIVE	08/03/13	55.56KB	Share
ATH	Appendix 3B		07/03/13	255.83KB	Share
ATH	Response to ASX Query	PRICE SENSITIVE	07/03/13	181.39KB	Share
ATH	Pranas PBT434 Inhibits PD Protein & Brain Cell Death	PRICE SENSITIVE	06/03/13	31.28KB	Share
ATH	Prana's PBT2 Reduces Tau Related Cognitive Impairment	PRICE SENSITIVE	04/03/13	29.74KB	Share
ATH	FORM 6-K		28/02/13	117.94KB	Share
ATH	Appendix 4D	PRICE SENSITIVE	27/02/13	1.36MB	Share
ATH	Prana to Present at Cowen & Company Health Care Conference		26/02/13	28.26KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/13	59.61KB	Share
ATH	Prana Announces NYAS Symposium eBriefing Available Online		30/01/13	31.48KB	Share
ATH	Prana Completes Recruitment in Huntington Trial	PRICE SENSITIVE	19/12/12	74.18KB	Share
ATH	Journal of Huntington's Disease Publishes Benefits of PBT2	PRICE SENSITIVE	13/12/12	76.07KB	Share
ATH	Change of Director's Interest Notice (GK,GM,BM,LG,PM)		12/12/12	121.62KB	Share
ATH	Appendix 3B and 708A Notice		12/12/12	190.99KB	Share
ATH	Results of Annual General Meeting		12/12/12	42.2KB	Share
ATH	AGM Presentation 2012		12/12/12	94.62KB	Share
ATH	New York Academy of Sciences Symposium Discusses PBT2	PRICE SENSITIVE	06/12/12	33.18KB	Share
ATH	Response to ASX Diversity Policy		30/11/12	201.87KB	Share
ATH	Prana Completes Recruitment in Alzheimer's Trial	PRICE SENSITIVE	27/11/12	31.79KB	Share
ATH	Prana to present at New York Academy of Science Symposium		20/11/12	29.2KB	Share
ATH	Prana Provides Huntington Disease Trial Update	PRICE SENSITIVE	14/11/12	34.22KB	Share
ATH	Notice of Annual General Meeting		09/11/12	430.2KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	29/10/12	149.16KB	Share
ATH	Ceasing to be a substantial holder		09/10/12	326.97KB	Share
ATH	Change in substantial holding		09/10/12	115.5KB	Share
ATH	Appendix 3B and Section 708A		08/10/12	287.71KB	Share
ATH	Revised table in 2012 Annual Report		08/10/12	260.33KB	Share
ATH	Form 20-F		05/10/12	2.24MB	Share
ATH	Prana Announces A$6.0 Million Capital Raising	PRICE SENSITIVE	01/10/12	29.24KB	Share
ATH	Trading Halt	PRICE SENSITIVE	01/10/12	94.09KB	Share
ATH	Annual Report 2012		28/09/12	3.85MB	Share
ATH	Prana Scientist to Participate in Webcast		28/09/12	186.65KB	Share
ATH	Appendix 3B and Section 708A Notice		26/09/12	288.09KB	Share
ATH	Further information - Clinical Trials Cited as Most Advanced		20/09/12	189.23KB	Share
ATH	Prana's PBT2 Clinical Trials Cited as Most Advanced		20/09/12	188.09KB	Share
ATH	Appendix 3B and Section 708A Notice		17/09/12	288.1KB	Share
ATH	Prana Receives Recommendation to Proceed with Clinical Trial	PRICE SENSITIVE	12/09/12	197.62KB	Share
ATH	Significant Promise in the Fight Against Alzheimer's Disease	PRICE SENSITIVE	11/09/12	43.65KB	Share
ATH	Appendix 3B and Section 708A Notice		03/09/12	288.55KB	Share
ATH	Appendix 4E - Preliminary Financial Report	PRICE SENSITIVE	31/08/12	137.42KB	Share
ATH	Prana's Parkinson's drug meets development milestone	PRICE SENSITIVE	30/08/12	54.58KB	Share
ATH	Appendix 3B and Section 708A Notice		27/08/12	288.42KB	Share
ATH	ABC Radio Program features Prana Alzheimer's disease trial		22/08/12	184.97KB	Share
ATH	Prana Provides Clinical Trials Update	PRICE SENSITIVE	22/08/12	157.9KB	Share
ATH	Appendix 4C - Quarterly report	PRICE SENSITIVE	31/07/12	58.79KB	Share
ATH	Prana's PBT2 presented at HDSA National Convention	PRICE SENSITIVE	13/06/12	226.88KB	Share
ATH	Prana to present at upcoming Australia and US conferences		01/06/12	217.65KB	Share
ATH	Appendix 3B and Section 708A Notice		25/05/12	100.62KB	Share
ATH	Appendix 3B and Section 708A Notice		21/05/12	101.35KB	Share
ATH	Results of General Meeting		18/05/12	43.68KB	Share
ATH	Dr. Rudy Tanzi to Discuss PBT2 Trial on Thursday, May 10		09/05/12	186.84KB	Share
ATH	Change of Director's Interest Notice - GK		04/05/12	76KB	Share
ATH	Prana Comments on Neurology Publication Huntington Data	PRICE SENSITIVE	01/05/12	205.91KB	Share
ATH	First Patient Enrolled in Phase II Huntington Disease Trial	PRICE SENSITIVE	30/04/12	187.99KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	27/04/12	57.62KB	Share
ATH	Notice of General Meeting/Proxy Form		17/04/12	117.15KB	Share
ATH	Appendix 3B and Section 708A Notice		29/03/12	101.64KB	Share
ATH	Appendix 3B and Section 708A Notice		21/03/12	101.67KB	Share
ATH	Prana Doses First Patient in the IMAGINE Phase II Trial	PRICE SENSITIVE	06/03/12	194.27KB	Share
ATH	Appendix 3B and Section 708A Notice		01/03/12	100.73KB	Share
ATH	Form 6-K		27/02/12	258.77KB	Share
ATH	Appendix 4D	PRICE SENSITIVE	24/02/12	854.6KB	Share
ATH	Appendix 3B and Section 708A Notice		16/02/12	100.64KB	Share
ATH	Appendix 3B and Section 708A Notice		10/02/12	100.66KB	Share
ATH	Section 708A Notice		09/02/12	32.74KB	Share
ATH	Section 708A Notice		08/02/12	32.74KB	Share
ATH	Appendix 3B and Section 708A Notice		07/02/12	100.77KB	Share
ATH	Prana comments on articles		02/02/12	230.4KB	Share
ATH	Prana Diversity Policy		01/02/12	63.65KB	Share
ATH	Appendix 3B and Section 708A Notice		01/02/12	101.23KB	Share
ATH	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/12	58.77KB	Share
ATH	Appendix 3B and Section 708A Notice		30/01/12	100.83KB	Share
ATH	Appendix 3B and Section 708A Notice		17/01/12	100.79KB	Share
ATH	Professor Tanzi Appointed Prana's Chief Scientific Advisor		11/01/12	188.92KB	Share
ATH	Section 708A Notice		11/01/12	32.86KB	Share
ATH	Section 708A Notice		10/01/12	29.67KB	Share
ATH	Appendix 3B and Section 708A Notice		09/01/12	101.18KB	Share
ATH	Change of Director's Interest Notice - GK		04/01/12	74.3KB	Share
ATH	FDA Approval to Commence Huntington's Disease Clinical Trial	PRICE SENSITIVE	04/01/12	217.41KB	Share
ATH	Appendix 3B and Section 708A Notice		22/12/11	100.18KB	Share
ATH	Appendix 3B		20/12/11	299.57KB	Share
ATH	Landmark Publication Endorses Prana's Strategy	PRICE SENSITIVE	16/12/11	219.01KB	Share

ATHSection 708A Notice
06/08/13		85.5KB	Share
ATHAppendix 3B
05/08/13		186.63KB	Share
ATHPrana prepares for next steps in the PBT2 development path
02/08/13		31.71KB	Share
ATHAppendix 4C - quarterly
31/07/13	PRICE SENSITIVE	61.38KB	Share
ATHPrana Doses 1st Patient in PBT2 Alzheimers Extension Study
29/07/13	PRICE SENSITIVE	30.03KB	Share
ATHPrana Completes Phase 2 Huntington Disease Trial with PBT2
23/07/13	PRICE SENSITIVE	32.24KB	Share
ATHPrana receives approval for open label extension study in AD
03/07/13	PRICE SENSITIVE	97.07KB	Share
ATHAppendix 3B and Section 708A Notice
28/06/13		187.32KB	Share
ATHPranas PBT434 shows potential as treatment in PD
20/06/13	PRICE SENSITIVE	1.18MB	Share
ATHNew benchmark test to assess HD patients in clincial trials
19/06/13	PRICE SENSITIVE	527.83KB	Share
ATHPrana Announces Share Purchase Plan Closed
03/05/13		30.29KB	Share
ATHAppendix 3B
03/05/13		186.66KB	Share
ATHAppendix 4C - quarterly
29/04/13	PRICE SENSITIVE	60.58KB	Share
ATHShare Purchase Plan 2013 Offer Document
11/04/13	PRICE SENSITIVE	220.56KB	Share
ATHCeasing to be a substantial holder
11/04/13		32.34KB	Share
ATHAppendix 3B
08/04/13		268.57KB	Share
ATHPrana Announces Successful A$7 milion Capital Raising
27/03/13	PRICE SENSITIVE	28.21KB	Share
ATHTrading Halt
27/03/13	PRICE SENSITIVE	159KB	Share
ATHPrana details PBT2 data on reduced Tau Cognitive Impairment
08/03/13	PRICE SENSITIVE	55.56KB	Share
ATHAppendix 3B
07/03/13		255.83KB	Share
ATHResponse to ASX Query
07/03/13	PRICE SENSITIVE	181.39KB	Share
ATHPranas PBT434 Inhibits PD Protein & Brain Cell Death
06/03/13	PRICE SENSITIVE	31.28KB	Share
ATHPrana's PBT2 Reduces Tau Related Cognitive Impairment
04/03/13	PRICE SENSITIVE	29.74KB	Share
ATHFORM 6-K
28/02/13		117.94KB	Share
ATHAppendix 4D
27/02/13	PRICE SENSITIVE	1.36MB	Share
ATHPrana to Present at Cowen & Company Health Care Conference
26/02/13		28.26KB	Share
ATHAppendix 4C - quarterly
31/01/13	PRICE SENSITIVE	59.61KB	Share
ATHPrana Announces NYAS Symposium eBriefing Available Online
30/01/13		31.48KB	Share
ATHPrana Completes Recruitment in Huntington Trial
19/12/12	PRICE SENSITIVE	74.18KB	Share
ATHJournal of Huntington's Disease Publishes Benefits of PBT2
13/12/12	PRICE SENSITIVE	76.07KB	Share
ATHChange of Director's Interest Notice (GK,GM,BM,LG,PM)
12/12/12		121.62KB	Share
ATHAppendix 3B and 708A Notice
12/12/12		190.99KB	Share
ATHResults of Annual General Meeting
12/12/12		42.2KB	Share
ATHAGM Presentation 2012
12/12/12		94.62KB	Share
ATHNew York Academy of Sciences Symposium Discusses PBT2
06/12/12	PRICE SENSITIVE	33.18KB	Share
ATHResponse to ASX Diversity Policy
30/11/12		201.87KB	Share
ATHPrana Completes Recruitment in Alzheimer's Trial
27/11/12	PRICE SENSITIVE	31.79KB	Share
ATHPrana to present at New York Academy of Science Symposium
20/11/12		29.2KB	Share
ATHPrana Provides Huntington Disease Trial Update
14/11/12	PRICE SENSITIVE	34.22KB	Share
ATHNotice of Annual General Meeting
09/11/12		430.2KB	Share
ATHAppendix 4C - quarterly
29/10/12	PRICE SENSITIVE	149.16KB	Share
ATHCeasing to be a substantial holder
09/10/12		326.97KB	Share
ATHChange in substantial holding
09/10/12		115.5KB	Share
ATHAppendix 3B and Section 708A
08/10/12		287.71KB	Share
ATHRevised table in 2012 Annual Report
08/10/12		260.33KB	Share
ATHForm 20-F
05/10/12		2.24MB	Share
ATHPrana Announces A$6.0 Million Capital Raising
01/10/12	PRICE SENSITIVE	29.24KB	Share
ATHTrading Halt
01/10/12	PRICE SENSITIVE	94.09KB	Share
ATHAnnual Report 2012
28/09/12		3.85MB	Share
ATHPrana Scientist to Participate in Webcast
28/09/12		186.65KB	Share
ATHAppendix 3B and Section 708A Notice
26/09/12		288.09KB	Share
ATHFurther information - Clinical Trials Cited as Most Advanced
20/09/12		189.23KB	Share
ATHPrana's PBT2 Clinical Trials Cited as Most Advanced
20/09/12		188.09KB	Share
ATHAppendix 3B and Section 708A Notice
17/09/12		288.1KB	Share
ATHPrana Receives Recommendation to Proceed with Clinical Trial
12/09/12	PRICE SENSITIVE	197.62KB	Share
ATHSignificant Promise in the Fight Against Alzheimer's Disease
11/09/12	PRICE SENSITIVE	43.65KB	Share
ATHAppendix 3B and Section 708A Notice
03/09/12		288.55KB	Share
ATHAppendix 4E - Preliminary Financial Report
31/08/12	PRICE SENSITIVE	137.42KB	Share
ATHPrana's Parkinson's drug meets development milestone
30/08/12	PRICE SENSITIVE	54.58KB	Share
ATHAppendix 3B and Section 708A Notice
27/08/12		288.42KB	Share
ATHABC Radio Program features Prana Alzheimer's disease trial
22/08/12		184.97KB	Share
ATHPrana Provides Clinical Trials Update
22/08/12	PRICE SENSITIVE	157.9KB	Share
ATHAppendix 4C - Quarterly report
31/07/12	PRICE SENSITIVE	58.79KB	Share
ATHPrana's PBT2 presented at HDSA National Convention
13/06/12	PRICE SENSITIVE	226.88KB	Share
ATHPrana to present at upcoming Australia and US conferences
01/06/12		217.65KB	Share
ATHAppendix 3B and Section 708A Notice
25/05/12		100.62KB	Share
ATHAppendix 3B and Section 708A Notice
21/05/12		101.35KB	Share
ATHResults of General Meeting
18/05/12		43.68KB	Share
ATHDr. Rudy Tanzi to Discuss PBT2 Trial on Thursday, May 10
09/05/12		186.84KB	Share
ATHChange of Director's Interest Notice - GK
04/05/12		76KB	Share
ATHPrana Comments on Neurology Publication Huntington Data
01/05/12	PRICE SENSITIVE	205.91KB	Share
ATHFirst Patient Enrolled in Phase II Huntington Disease Trial
30/04/12	PRICE SENSITIVE	187.99KB	Share
ATHAppendix 4C - quarterly
27/04/12	PRICE SENSITIVE	57.62KB	Share
ATHNotice of General Meeting/Proxy Form
17/04/12		117.15KB	Share
ATHAppendix 3B and Section 708A Notice
29/03/12		101.64KB	Share
ATHAppendix 3B and Section 708A Notice
21/03/12		101.67KB	Share
ATHPrana Doses First Patient in the IMAGINE Phase II Trial
06/03/12	PRICE SENSITIVE	194.27KB	Share
ATHAppendix 3B and Section 708A Notice
01/03/12		100.73KB	Share
ATHForm 6-K
27/02/12		258.77KB	Share
ATHAppendix 4D
24/02/12	PRICE SENSITIVE	854.6KB	Share
ATHAppendix 3B and Section 708A Notice
16/02/12		100.64KB	Share
ATHAppendix 3B and Section 708A Notice
10/02/12		100.66KB	Share
ATHSection 708A Notice
09/02/12		32.74KB	Share
ATHSection 708A Notice
08/02/12		32.74KB	Share
ATHAppendix 3B and Section 708A Notice
07/02/12		100.77KB	Share
ATHPrana comments on articles
02/02/12		230.4KB	Share
ATHPrana Diversity Policy
01/02/12		63.65KB	Share
ATHAppendix 3B and Section 708A Notice
01/02/12		101.23KB	Share
ATHAppendix 4C - quarterly
31/01/12	PRICE SENSITIVE	58.77KB	Share
ATHAppendix 3B and Section 708A Notice
30/01/12		100.83KB	Share
ATHAppendix 3B and Section 708A Notice
17/01/12		100.79KB	Share
ATHProfessor Tanzi Appointed Prana's Chief Scientific Advisor
11/01/12		188.92KB	Share
ATHSection 708A Notice
11/01/12		32.86KB	Share
ATHSection 708A Notice
10/01/12		29.67KB	Share
ATHAppendix 3B and Section 708A Notice
09/01/12		101.18KB	Share
ATHChange of Director's Interest Notice - GK
04/01/12		74.3KB	Share
ATHFDA Approval to Commence Huntington's Disease Clinical Trial
04/01/12	PRICE SENSITIVE	217.41KB	Share
ATHAppendix 3B and Section 708A Notice
22/12/11		100.18KB	Share
ATHAppendix 3B
20/12/11		299.57KB	Share
ATHLandmark Publication Endorses Prana's Strategy
16/12/11	PRICE SENSITIVE	219.01KB	Share

REFRESH

First 5 6 7 8 9

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.5¢		Change 0.000(0.00%)		Mkt cap ! $138.1M

Open	High	Low	Value	Volume
1.5¢	1.5¢	1.4¢	$78.43K	5.408M

Buyers (Bids)

No.	Vol.	Price($)
12	3821756	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	18525057	12

View Market Depth

No.	Vol.	Price($)
12	3821756	0.014
41	22484464	0.013
35	16124733	0.012
21	12829327	0.011
35	15758355	0.010

Price($)	Vol.	No.
0.015	18525057	12
0.016	4385271	15
0.017	7458592	11
0.018	12761167	22
0.019	10345967	12

Last trade - 14.36pm 11/08/2025 (20 minute delay)


Last 1.4¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
1.4¢	1.5¢	1.4¢	2227207
Last updated 15.02pm 11/08/2025 ?

ATH (ASX) Chart

ALTERITY THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories